Biosimilar Testing Services Market Report 2026

The biosimilar testing services market size has grown rapidly in recent years. It will grow from $1.84 billion in 2025 to $2.08 billion in 2026 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to expansion of biosimilar development pipelines, increasing regulatory approvals of biosimilars, growth of biologics manufacturing, rising reliance on CRO testing services, improvements in analytical testing technologies.

The biosimilar testing services market size is expected to see rapid growth in the next few years. It will grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to growing demand for cost-effective biologic alternatives, expansion of global biosimilar markets, increasing complexity of biologic molecules, rising focus on comparability studies, growing investments in biosimilar R&D. Major trends in the forecast period include increasing demand for comprehensive analytical characterization, rising adoption of advanced bioanalytical assays, growing emphasis on regulatory-compliant testing services, expansion of outsourced biosimilar development support, enhanced focus on method validation and consistency.

The rising prevalence of autoimmune diseases is expected to drive the growth of the biosimilar testing services market going forward. Autoimmune diseases are disorders in which the body’s immune system mistakenly attacks its own healthy cells and tissues, resulting in inflammation and tissue damage. The increasing prevalence of autoimmune diseases is attributed to the growing demand for effective biologic therapies that manage chronic symptoms, reduce flare-ups, and improve long-term patient outcomes. Biosimilar testing services support the treatment of autoimmune diseases by ensuring that biosimilars are safe, effective, and comparable to original biologics, providing affordable and accessible therapeutic options. For instance, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, it is estimated that 562,378 Australians will be living with rheumatoid arthritis (RA) in 2025, representing 14% of all arthritis cases that year. By 2040, this figure is projected to increase by 33% to 748,721 people, an additional 186,343 Australians with RA compared with 2025. Therefore, the growing prevalence of autoimmune diseases is fueling the growth of the biosimilar testing services market.

Major companies operating in the biosimilar testing services market are focusing on expanding facilities to introduce new technologies and capabilities that enhance productivity and competitiveness. Facility expansion involves enlarging or upgrading existing infrastructure to meet increased operational demands or future growth requirements. For instance, in October 2023, Tanvex BioPharma USA Inc., a US-based biotechnology company, launched Tanvex CDMO, a state-of-the-art contract development and manufacturing organization in San Diego, providing end-to-end biologics development and manufacturing services, including cell line development, process optimization, analytical testing, and regulatory support. This facility aims to accelerate the development of biopharmaceutical products from concept to commercial scale, leveraging advanced technologies and expert teams to deliver innovative biologics to patients worldwide.

In September 2023, Cerba HealthCare SA, a France-based clinical trial laboratory and diagnostics provider, acquired Cirion Biopharma Inc. for an undisclosed amount. Through this acquisition, Cerba HealthCare SA intends to expand its bioanalytical capabilities in biosimilars and biologics development, strengthen its presence in North America, and enhance PK/PD and immunogenicity testing for complex clinical trials. Cirion Biopharma Inc. is a Canada-based contract research organization that provides bioanalytical services, PK/PD and immunogenicity testing, specimen management, and R&D support from preclinical discovery through phase IV trials.

Major companies operating in the biosimilar testing services market are Thermo Fisher Scientific Inc., IQVIA Laboratories, Laboratory Corporation of America Holdings, Eurofins Scientific SE, SGS Société Générale de Surveillance SA, WuXi AppTec Co. Ltd., Intertek Group plc, Samsung Biologics Co. Ltd., Almac Group Limited, Syngene International Limited, Shanghai Medicilon Inc., Kymos Group S.L., Pacific BioLabs Inc., Profacgen Inc., ExcellGene SA, BioPharmaSpec Ltd., Charles River Laboratories International Inc., Covance Inc., PPD Inc., ICON plc, Parexel International Corporation, Frontage Laboratories Inc.

North America was the largest region in the biosimilar testing services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilar testing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biosimilar testing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the biosimilar testing services market by increasing costs of imported analytical instruments, reference standards, reagents, consumables, and laboratory automation systems. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on imported high-end testing equipment, while Asia-Pacific faces cost pressures in service delivery and export-oriented testing. These tariffs are increasing service pricing and extending project timelines. However, they are also encouraging regional laboratory expansion, local instrument sourcing, and investment in domestic analytical testing capabilities.

The biosimilar testing services market research report is one of a series of new reports that provides biosimilar testing services market statistics, including biosimilar testing services industry global market size, regional shares, competitors with a biosimilar testing services market share, detailed biosimilar testing services market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar testing services industry. This biosimilar testing services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biosimilar testing services refer to the scientific processes and analytical evaluations conducted to determine the similarity between a biosimilar and its reference biological product. These services involve a comprehensive assessment of various attributes, including structural, functional, and biological characteristics, to ensure consistency, quality, and safety. The goal is to confirm that the biosimilar matches the reference product in terms of efficacy and immunogenicity, while adhering to regulatory standards.

The primary service types of biosimilar testing services are analytical testing, bioanalytical testing, stability testing, method development and validation, and others. Analytical testing refers to a comprehensive set of laboratory techniques used to assess the structural and functional similarity between biosimilars and reference biologics, ensuring product quality, safety, and efficacy. These services leverage multiple technologies, including cell-based assays, chromatography techniques, mass spectrometry, and bioassays. They are applied to different molecule types such as monoclonal antibodies, recombinant hormones, insulin, interferons, enzymes, and others. Applications span oncology, autoimmune diseases, blood disorders, growth hormone deficiency, and other therapeutic areas, serving various end users, including pharmaceutical companies, biotechnology companies, contract research organizations, academic research institutes, and government agencies.

The biosimilar testing services market consists of revenues earned by entities by providing services such as comparability testing, structural characterization, functional characterization, impurity profiling, glycosylation analysis, pharmacokinetic studies, immunogenicity assessment, and regulatory compliance support. The market value includes the value of related goods sold by the service provider or included within the service offering. The biosimilar testing services market also includes sales of reference biologics, biosimilar candidates, assay kits, analytical reagents, detection reagents, and bioanalytical instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.